Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible
In a groundbreaking development for cancer treatment in India, Zydus Lifesciences has launched Olaparib under the brand name IBYRA, a pioneering PARP inhibitor designed to ... Read More
CureMatch, Spesana forge partnership to revolutionize precision medicine
In a groundbreaking development for the healthcare industry, CureMatch and Spesana have announced a strategic partnership aimed at advancing precision medicine and transforming patient care ... Read More
Immune-Onc Therapeutics gets FDA orphan drug status for IO-202 in CMML
Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology, has achieved a significant milestone with the ... Read More
Kinnate Biopharma agrees to merger with XOMA, boosting shareholder value and advancing cancer research
Kinnate Biopharma Inc. (Nasdaq: KNTE), a leading clinical-stage precision oncology company, has announced a definitive merger agreement with XOMA Corporation, setting the stage for a ... Read More
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license ... Read More
G1 Therapeutics’ Phase 3 trial of trilaciclib for metastatic triple negative breast cancer continues as planned
In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in cancer treatment, announced the continuation of its ... Read More
Jazz Pharmaceuticals to acquire Redx Pharma’s KRAS inhibitor program to expand oncology pipeline
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have entered into a definitive agreement, marking a significant milestone in the development of ... Read More
Nanobiotix achieves milestone in cancer treatment with NBTXR3, secures $20m from Janssen
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a leader in the field of biotechnology, announced a significant achievement in its ongoing pivotal Phase 3 study, NANORAY-312. ... Read More
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More